Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravaginal Prasterone for VVA in Breast Cancer Patients on AIs
NCT03740945Phase 3Withdrawn
- Sponsor
- Endoceutics
- Start
- Nov 2018
- Primary completion
- Dec 2019
- Modality
- Allosteric Modulators
01
Overview
A Phase 3 trial of prasterone in Vulvovaginal atrophy (VVA), sponsored by Endoceutics. Planned start Nov 2018; status: withdrawn.
02
Drugs
prasterone
03
Conditions
Vulvovaginal atrophy (VVA)
Beyond the preview
Go deeper on NCT03740945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03740945.